Sight Sciences, Inc. (SGHT)
Automate Your Wheel Strategy on SGHT
With Tiblio's Option Bot, you can configure your own wheel strategy including SGHT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Published: March 06, 2026 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Sight Sciences, Inc. (NASDAQ: SGHT). The investigation focuses on Sight Sciences executive officers and whether investor losses may be recovered under federal securities laws.
Read More
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Published: December 31, 2025 by: Seeking Alpha
Sentiment: Positive
Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances.
Read More
What Makes Sight Sciences, Inc. (SGHT) a Strong Momentum Stock: Buy Now?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Does Sight Sciences, Inc. (SGHT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Read More
Sight Sciences (SGHT) Upgraded to Buy: Here's What You Should Know
Published: November 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Sight Sciences (SGHT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use
Published: September 17, 2025 by: GlobeNewsWire
Sentiment: Neutral
MENLO PARK, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the European Journal of Ophthalmology of a systematic review and meta-analysis of the clinical effectiveness, safety, humanistic and economic impact of the OMNI Surgical System (OMNI).
Read More
Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research Cost-Utility Analysis published in the Expert Review of Pharmacoeconomics and Outcomes Research
Read More
About Sight Sciences, Inc. (SGHT)
- IPO Date 2021-07-15
- Website https://www.sightsciences.com
- Industry Medical - Devices
- CEO Paul Badawi
- Employees 216